Alopecia areata is an autoimmune condition in which the immune system mistakenly attacks hair follicles, causing hair loss. It affects approximately 6.8 million Americans and can strike at any age, in any gender, at any time, often with little warning.
What Causes Alopecia Areata?
Hair follicles normally have “immune privilege”, they suppress immune activity to prevent the immune system from targeting hair growth cells. In alopecia areata, this privilege breaks down. T lymphocytes invade the follicle and disrupt the hair growth cycle, causing the follicle to enter a dormant state.
The precise trigger is not fully understood, but genetic factors, stress, viral infections, and other immune dysregulation events have been implicated.
Patterns of Hair Loss
- Alopecia areata: Patchy hair loss, most commonly on the scalp
- Alopecia totalis: Complete scalp hair loss
- Alopecia universalis: Loss of all hair on the entire body
The condition is unpredictable, hair may regrow spontaneously, respond to treatment, or progress. Even after years without hair, regrowth remains biologically possible because follicles are suppressed, not destroyed.
The Treatment Revolution: JAK Inhibitors
For decades, treatment options were limited to corticosteroids and contact immunotherapy, with inconsistent results and no approved therapy.
In 2022 and 2023, the FDA approved the first medications specifically for alopecia areata: ritlecitinib (Litfulo) and baricitinib (Olumiant), both JAK inhibitors. These inhibit the inflammatory signaling pathway driving follicular attack, producing hair regrowth in a substantial proportion of patients with moderate to severe alopecia areata.
Ask NuLine about skin and hair condition research to learn about clinical trial opportunities.